Gemcitabine-hydrochloride-LY-188011-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
Gemcitabine-hydrochloride-LY-188011-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
Gemcitabine-hydrochloride-LY-188011-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
Gemcitabine-hydrochloride-LY-188011-hydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress_第4頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEGemcitabinehydrochlorideCat.No.:HY-B0003CASNo.:122111-03-9Synonyms:LY188011hydrochloride分?式:C?H??ClF?N?O?分?量:299.66作?靶點(diǎn):DNA/RNASynthesis;NucleosideAntimetabolite/Analog;Autophagy;Apoptosis作?通路:CellCycle/DNADamage;Autophagy;Apoptosis儲(chǔ)存?式:4°C,sealedstorage,awayfrommoistureandlight*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoistureandlight)溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:33.33mg/mL(111.23mM;Needultrasonic)DMSO:25mg/mL(83.43mM;ultrasonicandwarmingandheatto60°C)DMF:2.5mg/mL(8.34mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM3.3371mL16.6856mL33.3712mL5mM0.6674mL3.3371mL6.6742mL10mM0.3337mL1.6686mL3.3371mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;?旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限:-80°C,6months;-20°C,1month(sealedstorage,awayfrommoistureandlight)。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請(qǐng)依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(6.94mM);Clearsolution2.請(qǐng)依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(6.94mM);Clearsolution3.請(qǐng)依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(6.94mM);Clearsolution4.請(qǐng)依序添加每種溶劑:PBSSolubility:60mg/mL(200.23mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性GemcitabineHydrochloride(LY188011Hydrochloride)?種嘧啶核苷類似物抗代謝藥(nucleosideantimetabolite/analog)和抗腫瘤劑。Gemcitabine抑制DNA合成(DNAsynthesis)和修復(fù),導(dǎo)致細(xì)胞?噬(autophagy)和凋亡(apoptosis)。IC50&TargetDNAsynthesis[1]體外研究GemcitabineHydrochloride(purchasedfromMedChemExpress,0.003-1μM;3days)killsbothmouseandhumansenescentcellseffectivelyandpotently[4].GemcitabineHydrochlorideinhibitsthegrowthofBxPC-3,MiaPaca-2,PANC-1,PL-45andAsPC-1cellswithIC50sof37.6,42.9,92.7,89.3and131.4nM,respectively[1].CellViabilityAssay[4]CellLine:Non-senescentandreplication-inducedsenescentnewborndermalfibroblasts(NBFs)Concentration:0.003,0.01,0.03,0.1,0.3,1μMIncubationTime:3daysResult:Killedreplication-inducedsenescentNBFsfor3dayswith11.0%cellviability.體內(nèi)研究GemcitabineHydrochloridecanbeadministeredviaendotrachealsprayinratswithoutmarkedtoxicitywithamaximumtolerateddoseof4mg/kgonceaweekfor9weeks.ThetoxicityofGemcitabineislowervialungthanoraladministrationatdosagesof2,4,and6mg/kg[2].TreatmentoftheLSL-KrasG12D/+;LSL-Trp53R172H;Pdx-1-CremicewitheitherGemcitabine(50mg/kg,i.p.)orthecombinationDMAPT/GemcitabineHydrochloridesignificantlyincreasesthemediansurvivaltimebymorethan30dayscomparedtotheplacebogroup(254.5or255daysvs.217.5days,respectively)[3].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Nature.2019Oct;574(7777):264-267.?CellRes.2020Jul;30(7):574-589.?AdvMater.2021May;33(18):e2100949.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?Gastroenterology.2021Nov;161(5):1601-1614.e23.?SciTranslMed.2021Jan20;13(577):eaba7401.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].WangH,etal.EnhancedefficacyofGemcitabinebyindole-3-carbinolinpancreaticcelllines:theroleofhumanequilibrativenucleosidetransporter1.AnticancerRes.2011Oct;31(10):3171-80[2].GagnadouxF,etal.Safetyofpulmonaryadministrationofgemcitabineinrats.JAerosolMed.2005Summer;18(2):198-206[3].LouM,etal.Physicalinteractionbetweenhumanribonucleotidereductaselargesubunitandthioredoxinincreasescolorectalcancermalignancy.JBiolChem.2017Jun2;292(22):9136-9149.[4].Yip-SchneiderMT,etal.DimethylaminoparthenolideandGemcitabine:asurvivalstudyusingageneticallyengineeredmousemodelofpancreaticcancer.BMCCancer.2013Apr17;13:194.McePdfH

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論